News
ImmuCell Announces Preliminary, Unaudited Sales Results for Second Quarter of 2022
PORTLAND, Maine, July 07, 2022 -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy...
ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders
PORTLAND, Maine, May 19, 2022 -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy...
ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2022
Q1 2022 Product Sales Increased 46% over Q1 2021PORTLAND, Maine, May 12, 2022 -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products...
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2022
Conference Call Scheduled for Friday, May 13, 2022 at 9:00 AM ETPORTLAND, Maine, May 10, 2022 -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically-proven and...
UPDATE — Dr. Mark Wustenberg joins ImmuCell as Commercial Leader of Stakeholder Engagement
PORTLAND, Maine, May 05, 2022 -- Certain immaterial corrections have been made to the second and fifth paragraphs. ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets...
Dr. Mark Wustenberg joins ImmuCell as Commercial Leader of Stakeholder Engagement
PORTLAND, Maine, May 05, 2022 -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy...
ImmuCell Announces Record Preliminary, Unaudited Sales Results for First Quarter of 2022
PORTLAND, Maine, April 11, 2022 -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy...
ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2021
Annual Product Sales for 2021 Increased 25% over 2020PORTLAND, Maine, Feb. 22, 2022 -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical...
ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2021
Conference Call Scheduled for Wednesday, February 23, 2022 at 9:00 AM ETPORTLAND, Maine, Feb. 16, 2022 -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically-proven...
ImmuCell Announces Record Preliminary, Unaudited Sales Results for the Year Ended December 31, 2021
PORTLAND, Maine, Jan. 05, 2022 -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy...